Biocon Limited has informed the Exchange regarding a press release dated February 24, 2025, titled "Biocon Biologics Launches Yesintek (ustekinumab-kfce) Biosimilar to Stelara? in the United States".
Press Release Feb 24 2025
Filed with NSE ·
6ix hasn’t read this filing yet.
Earlier from Biocon
- Press Release Feb 11 2025
- Press Release Feb 06 2025
- Press Release Jan 30 2025
- Press Release Jan 27 2025
- Press Release Jan 09 2025
Later from Biocon
- Biocon Limited Press Release Feb 28 2025
- Press Release Mar 04 2025
- Press Release Mar 06 2025
- Press Release Mar 07 2025
- Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
Follow Biocon into a list and get an email when it puts out news.
Follow Biocon